Completed PHASE2 INTERVENTIONAL 1-arm NCT01349231

Ketamine Infusion for Obsessive-Compulsive Disorder

Sponsor: National Alliance for Research on Schizophrenia and Depression

Conditions Obsessive-compulsive Disorder

Interventions ketamine

Updated 7 times since 2017 Last updated: May 8, 2014 Started: Feb 28, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01349231, this PHASE2 trial focuses on Obsessive-compulsive Disorder and remains completed. Sponsored by National Alliance for Research on Schizophrenia and Depression, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Alliance for Research on Schizophrenia and Depression
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States